the STEM cell therapy for TRAumatic brain injury (STEMTRA) Trial

SanBio Announces Publication Comparing Outcome Measures for Persons With Chronic Traumatic Brain Injury in Expert Review of Neurotherapeutics

Retrieved on: 
Monday, November 1, 2021
Research, General Health, Pharmaceutical, Genetics, Publishing, Surgery, Clinical Trials, Science, Biotechnology, Communications, Stem Cells, Health, Other Science, Safety, Medication, Glasgow Outcome Scale, Brain, Marketing, Physical, Stem cell, Incidence, Death, Traumatic brain injury, Quality of life, Pharmaceuticals and Medical Devices Agency, Disease, Disability, Company, Biologics license application, Stroke, Regenerative medicine, Hospital, DRS, Disability Rating Scale, Physician, Rehabilitation, Microsoft, Tissue (biology), Global Burden of Disease Study, MCID, Â, Code of Federal Regulations, University of Wisconsin School of Medicine and Public Health, Medicines and Healthcare products Regulatory Agency, Person, Patient, Adult, Headache, Trauma, Medical College of Wisconsin, TBI, Health insurance, Pharmaceutical industry, Medical device, Wood drying, the STEM cell therapy for TRAumatic brain injury (STEMTRA) Trial, Traumatic Brain Injury, SB623, SanBio Group (SanBio Co., Ltd., SanBio, Inc. and SanBio Asia Pte. Ltd.), THE STEM CELL THERAPY FOR TRAUMATIC BRAIN INJURY (STEMTRA) TRIAL, TRAUMATIC BRAIN INJURY, SB623, SANBIO GROUP (SANBIO CO., LTD., SANBIO, INC. AND SANBIO ASIA PTE. LTD.)

The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan , SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte.

Key Points: 
  • The SanBio Group (SanBio Co., Ltd. of Tokyo, Japan , SanBio, Inc. of Mountain View, California, US, and SanBio Asia Pte.
  • Ltd. of Singapore) (TOKYO:4592), hereby announce that data comparing outcome measures for persons with traumatic brain injury (TBI) living with chronic motor deficits was published in Expert Review of Neurotherapeutics.
  • The publication, entitled, Determining minimally clinically important differences (MCIDs) for outcome measures in patients with chronic motor deficits secondary to traumatic brain injury, determined MCIDs for DRS and FMMS.
  • At SanBio, we are passionate about improving the lives of persons living with long-term motor deficits as a result of a TBI or stroke.

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

Retrieved on: 
Tuesday, January 5, 2021
Stem cells, Medical Supplies, Biotechnology, Managed care, Health, Pharmaceutical, Research, Hospitals, Genetics, Science, Clinical trials, Emerging technologies, the STEM cell therapy for TRAumatic brain injury (STEMTRA) Trial, Traumatic Brain Injury, SB623, SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)

The full manuscript, entitled Cell Therapy for Chronic TBI: Interim Analysis of the Randomized Controlled STEMTRA Trial can be accessed here .

Key Points: 
  • The full manuscript, entitled Cell Therapy for Chronic TBI: Interim Analysis of the Randomized Controlled STEMTRA Trial can be accessed here .
  • In the six-month, pre-specified interim analysis, treatment with SB623 cells appeared to be safe and well-tolerated.
  • The publication of the interim analysis results of the STEMTRA trial in Neurology is a significant step going forward.
  • Importantly, we believe publication of the STEMTRA interim results underscores the potential for cell therapy to improve the mobility for chronic TBI patients.